Campos-Gutiérrez RI, Castillón-Benavides NK, Cerda-Reyes S, Maldonado-Hernández JG, Cuevas-Mora HA, Trejo-Uribe V

Language: Spanish
References: 16
Page: 37-42
PDF size: 188.69 Kb.

ABSTRACT

Introduction: eosinophilic asthma is the most common phenotype of severe asthma. Benralizumab was approved on August 2019 for its use in Mexico as a complementary treatment for severe uncontrolled asthma with eosinophilic phenotype in adult patients. Objective: the objective of this study is to evaluate the efficacy and safety of Benralizumab in patients with severe eosinophilic asthma in the Mexican population. Material and methods: this is a descriptive observational study with a 12-month follow-up in Mexican adult patients who attend the Allergy and Clinical Immunology consultation of the Unit of Medical Specialties (SEDENA) with diagnosis of severe uncontrolled eosinophilic asthma, in whom benralizumab 30 mg subcutaneous (SC) was administered for a period of 12 months. Results: this report includes the results observed in three patients with uncontrolled severe eosinophilic asthma, who received treatment with benralizumab 30 mg for a period of 12 months. A pulmonary, clinical and laboratory functional evaluation was performed 12 months after treatment. The use of benralizumab decreased the number of exacerbations by 95.2% from baseline and 66.7% of the patients did not present any exacerbation during the year in which they received treatment with benralizumab. Improvement in asthma control was also documented, all patients showed improvement in the ACT questionnaire, on average of 12 points and 66.7% (two patients) reached an ACT ≥ 20. In the ACQ-5 questionnaire at 12 months of treatment, the patients presented a decrease in the score of 2.73. Likewise, a reduction in the percentage of the use of systemic steroid cycles in our patients of 87.5% was documented, and 66.7% of the patients were free of steroid use during the year of treatment. Regarding lung function, 100% of the patients had a notable improvement in lung function, an average of 561 mL in FEV1 pre-bronchodilator. Conclusion: this study confirms the efficacy and safety of benralizumab in real life, improving the control, quality of life and lung function of patients with severe eosinophilic asthma, without documented adverse effects related to its administration at 12 months.

REFERENCES

1. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bachalier L et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's severe asthma research program. J Allergy Clin Immunol. 2007; 119 (2): 405-413.

2. Global Initiative for Asthma. Global strategy for asthma management and prevention. update 2020.

3. Howrylak JA, Moll M, Weiss ST, Raby BA, Wu W, Xing EP. Gene expression profiling of asthma phenotypes demonstrates molecular signatures of atopy and asthma control. J Allergy Clin Immunol. 2016; 137 (5): 1390-1397.e6.

4. Hams E, Fallon PG. Innate type 2 cells and asthma. Curr Opin Pharmacol. 2012; 12 (4): 503-509.

5. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008; 118 (11): 3546-3556.

6. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015; 135 (4): 896-902.

7. Dávila-González I, Moreno-Benítez F, Quirce S. Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Invest Allergol Clin Immunol. 2019; 29 (2): 84-93.

8. Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des Devel Ther. 2018; 12: 619-628.

9. Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019; 20 (1): 179.

10. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM et al. MEDI-563 a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010; 125 (6): 1344-1135.

11. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013; 132 (5): 1086-1096.

12. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43: 343-373.

13. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388: 2115-2127.

14. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388: 2128-2141.

15. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017; 376: 2448-2458.

16. Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019; 7: 46-59.